FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1986396398> ?p ?o ?g. }

• W1986396398 endingPage "267" @default.
• W1986396398 startingPage "261" @default.
• W1986396398 abstract "Carcinoid tumors have a predilection for metastasizing to the liver. The presence of liver metastases is associated with poor prognosis and also results in significant deterioration of patient's quality of life. Several reports suggest that hepatic artery embolization or chemoembolization can be used for control of liver disease in these patients. We retrospectively reviewed our experience with the use of hepatic arterial embolization or chemoembolization in patients with liver-dominant metastatic carcinoid disease, evaluating the clinical and radiologic response rates, duration of response, and progression-free and overall survival rates of these patients.The medical records of all patients with carcinoid tumors metastatic to the liver who underwent hepatic artery embolization or chemoembolization between January 1992 and December 2000 were reviewed. For the purposes of this study, we compared the follow-up computed tomography or magnetic resonance imaging with the baseline imaging to determine each patient's objective tumor response. The interval between the dates of response and disease progression was considered the response duration. Progression-free survival duration was calculated from the date of initial treatment to the date disease progression was recorded or the date of death. Survival durations were calculated using the Kaplan-Meier method.Eighty-one patients (48 men and 33 women; age range, 38-79 years) were included in this study. The mean duration of disease from the initial discovery of liver metastases until embolization was 24.5 months. Fifty patients were treated with bland hepatic artery embolization, and 31 underwent chemoembolization. Of the 69 patients in whom radiologic response could be evaluated, partial response was observed in 46 patients (67%), minimal response (MR) in six (8.7%), stable disease in 11 (16%), and progressive disease in six (8.7%). The median duration of response in the 42 patients with partial response was 17 months (range, 4-51 months). Sixty-three percent of patients had a reduction in their tumor-related symptoms. The median progression-free survival duration was 19 months (95% confidence interval, 17-21 months); the probability of progression-free survival was 75%, 35%, and 11% at 1, 2, and 3 years, respectively. The median overall survival time was 31 months (95% confidence interval, 23-38 months); the survival probability was 93% at 1 year, 62% at 2 years, and 24% at 5 years.Hepatic arterial occlusive therapy using hepatic artery embolization or chemoembolization results in symptomatic and radiologic response in most patients with carcinoid metastases in the liver. The progression-free survival of 19 months achieved with embolization in our study is encouraging, given that most patients had extensive liver involvement and had shown disease progression while receiving systemic treatment." @default.
• W1986396398 created "2016-06-24" @default.
• W1986396398 creator A5002087124 @default.
• W1986396398 creator A5002650017 @default.
• W1986396398 creator A5009068086 @default.
• W1986396398 creator A5020745931 @default.
• W1986396398 creator A5034845901 @default.
• W1986396398 creator A5040833374 @default.
• W1986396398 creator A5043014076 @default.
• W1986396398 creator A5043534982 @default.
• W1986396398 creator A5044064524 @default.
• W1986396398 date "2003-07-01" @default.
• W1986396398 modified "2023-10-02" @default.
• W1986396398 title "Hepatic Artery Embolization and Chemoembolization for Treatment of Patients with Metastatic Carcinoid Tumors" @default.
• W1986396398 cites W1771569409 @default.
• W1986396398 cites W1922426788 @default.
• W1986396398 cites W1971397093 @default.
• W1986396398 cites W1973024626 @default.
• W1986396398 cites W1990076241 @default.
• W1986396398 cites W1990440729 @default.
• W1986396398 cites W1991357429 @default.
• W1986396398 cites W1996180982 @default.
• W1986396398 cites W2007949202 @default.
• W1986396398 cites W2015951789 @default.
• W1986396398 cites W2045173749 @default.
• W1986396398 cites W2062560558 @default.
• W1986396398 cites W2069932251 @default.
• W1986396398 cites W2081457024 @default.
• W1986396398 cites W2086241921 @default.
• W1986396398 cites W2086648036 @default.
• W1986396398 cites W2090757140 @default.
• W1986396398 cites W2091065621 @default.
• W1986396398 cites W2096864266 @default.
• W1986396398 cites W2101761640 @default.
• W1986396398 cites W2150002918 @default.
• W1986396398 cites W2167785546 @default.
• W1986396398 cites W2268362926 @default.
• W1986396398 doi "https://doi.org/10.1097/00130404-200307000-00008" @default.
• W1986396398 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12967136" @default.
• W1986396398 hasPublicationYear "2003" @default.
• W1986396398 type Work @default.
• W1986396398 sameAs 1986396398 @default.
• W1986396398 citedByCount "181" @default.
• W1986396398 countsByYear W19863963982012 @default.
• W1986396398 countsByYear W19863963982013 @default.
• W1986396398 countsByYear W19863963982014 @default.
• W1986396398 countsByYear W19863963982015 @default.
• W1986396398 countsByYear W19863963982016 @default.
• W1986396398 countsByYear W19863963982017 @default.
• W1986396398 countsByYear W19863963982018 @default.
• W1986396398 countsByYear W19863963982019 @default.
• W1986396398 countsByYear W19863963982020 @default.
• W1986396398 countsByYear W19863963982021 @default.
• W1986396398 countsByYear W19863963982022 @default.
• W1986396398 countsByYear W19863963982023 @default.
• W1986396398 crossrefType "journal-article" @default.
• W1986396398 hasAuthorship W1986396398A5002087124 @default.
• W1986396398 hasAuthorship W1986396398A5002650017 @default.
• W1986396398 hasAuthorship W1986396398A5009068086 @default.
• W1986396398 hasAuthorship W1986396398A5020745931 @default.
• W1986396398 hasAuthorship W1986396398A5034845901 @default.
• W1986396398 hasAuthorship W1986396398A5040833374 @default.
• W1986396398 hasAuthorship W1986396398A5043014076 @default.
• W1986396398 hasAuthorship W1986396398A5043534982 @default.
• W1986396398 hasAuthorship W1986396398A5044064524 @default.
• W1986396398 hasConcept C126322002 @default.
• W1986396398 hasConcept C126838900 @default.
• W1986396398 hasConcept C141071460 @default.
• W1986396398 hasConcept C143409427 @default.
• W1986396398 hasConcept C195910791 @default.
• W1986396398 hasConcept C2776035437 @default.
• W1986396398 hasConcept C2778822529 @default.
• W1986396398 hasConcept C2779134260 @default.
• W1986396398 hasConcept C2779319517 @default.
• W1986396398 hasConcept C71924100 @default.
• W1986396398 hasConceptScore W1986396398C126322002 @default.
• W1986396398 hasConceptScore W1986396398C126838900 @default.
• W1986396398 hasConceptScore W1986396398C141071460 @default.
• W1986396398 hasConceptScore W1986396398C143409427 @default.
• W1986396398 hasConceptScore W1986396398C195910791 @default.
• W1986396398 hasConceptScore W1986396398C2776035437 @default.
• W1986396398 hasConceptScore W1986396398C2778822529 @default.
• W1986396398 hasConceptScore W1986396398C2779134260 @default.
• W1986396398 hasConceptScore W1986396398C2779319517 @default.
• W1986396398 hasConceptScore W1986396398C71924100 @default.
• W1986396398 hasIssue "4" @default.
• W1986396398 hasLocation W19863963981 @default.
• W1986396398 hasLocation W19863963982 @default.
• W1986396398 hasOpenAccess W1986396398 @default.
• W1986396398 hasPrimaryLocation W19863963981 @default.
• W1986396398 hasRelatedWork W1986396398 @default.
• W1986396398 hasRelatedWork W2003938723 @default.
• W1986396398 hasRelatedWork W2047967234 @default.
• W1986396398 hasRelatedWork W2118496982 @default.
• W1986396398 hasRelatedWork W2349893477 @default.
• W1986396398 hasRelatedWork W2368694995 @default.
• W1986396398 hasRelatedWork W2394259972 @default.
• W1986396398 hasRelatedWork W2439875401 @default.

• next